Sign Out
Treatment of patients with acromegaly who are adequately controlled on SC treatment with Sandostatin; patients in whom surgery, radiotherapy or dopamine agonist treatment is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective (see Dosage & Administration).
Treatment of patients with symptoms associated with functional gastroenteropancreatic endocrine tumours in whom symptoms are adequately controlled on SC treatment with Sandostatin: Carcinoid tumours with features of the carcinoid syndrome; VIPomas; glucagonomas; gastrinomas/Zollinger-Ellison syndrome; insulinomas, for preoperative control of hypoglycaemia and for maintenance therapy; and GRFomas.
Treatment of patients with advanced neuroendocrine tumors of the midgut; or of unknown primary where non-midgut sites of origin have been excluded. Currently data does not support the use of Sandostatin as antitumor therapy in patients with pancreatic neuroendocrine tumours.
Continue with Google